CO5560533A2 - Preparacion de una composicion farmaceutica de liberacion sostenida - Google Patents

Preparacion de una composicion farmaceutica de liberacion sostenida

Info

Publication number
CO5560533A2
CO5560533A2 CO04016759A CO04016759A CO5560533A2 CO 5560533 A2 CO5560533 A2 CO 5560533A2 CO 04016759 A CO04016759 A CO 04016759A CO 04016759 A CO04016759 A CO 04016759A CO 5560533 A2 CO5560533 A2 CO 5560533A2
Authority
CO
Colombia
Prior art keywords
sustained release
pharmaceutically active
release apparatus
silicone
preparation
Prior art date
Application number
CO04016759A
Other languages
English (en)
Inventor
Serge R Martinod
Brandon Malcolm
Robert V Packard
Original Assignee
Smart Drug Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smart Drug Systems Inc filed Critical Smart Drug Systems Inc
Publication of CO5560533A2 publication Critical patent/CO5560533A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1.- Un aparato de liberación sostenida que comprende un material de soporte de silicona; y una composición farmacéuticamente activa transportada dentro del material de soporte de silicona o sobre él;comprendiendo la composición farmacéuticamente activa por lo menos un componente farmacéuticamente activo; y opcionalmente un transportador para el mismo;estando presente el componente farmacéuticamente activo en cantidades de desde aproximadamente 30% a 75% en peso, basado en el peso total del aparato de liberación sostenida.2.- Un aparato de liberación sostenida de acuerdo con la Reivindicación 1, en donde el aparato es del tipo de bastoncillo cubierto o no cubierto, o matriz dispersada.3.- Un aparato de liberación sostenida de acuerdo con la Reivindicación 2, en donde el aparato adopta la forma de un bastoncillo que lleva un recubrimiento de silicona sobre él.4.- Un aparato de liberación sostenida de acuerdo con la Reivindicación 1, en donde el componente farmacéuticamente activo está presente en cantidades de desde aproximadamente 40% a 50% en peso, basado en el peso total del aparato.5.- Un aparato de liberación sostenida de acuerdo con la Reivindicación 1, en donde el material de soporte de silicona se forma de un polímero a base de silicona.
CO04016759A 2001-09-11 2004-02-25 Preparacion de una composicion farmaceutica de liberacion sostenida CO5560533A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPR761401 2001-09-11

Publications (1)

Publication Number Publication Date
CO5560533A2 true CO5560533A2 (es) 2005-09-30

Family

ID=3831520

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04016759A CO5560533A2 (es) 2001-09-11 2004-02-25 Preparacion de una composicion farmaceutica de liberacion sostenida

Country Status (9)

Country Link
US (1) US20040234572A1 (es)
EP (1) EP1424994A4 (es)
JP (1) JP2005505557A (es)
CN (1) CN1541090A (es)
BR (1) BR0212052A (es)
CA (1) CA2452194A1 (es)
CO (1) CO5560533A2 (es)
NZ (1) NZ530550A (es)
WO (1) WO2003022242A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US20050129728A1 (en) * 2001-09-11 2005-06-16 Martinod Serge R. Sustained release pharmaceutical composition
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
JP2008500973A (ja) * 2004-05-31 2008-01-17 スマート ドラッグ システムズ インコーポレイティド 持続放出組成物
WO2005123120A1 (en) * 2004-06-16 2005-12-29 Smart Drug Systems Inc. Sustained release vaccine composition
AU2005269988B2 (en) 2004-07-02 2012-02-02 Mati Therapeutics Inc. Treatment medium delivery device and methods for delivery
WO2006078320A2 (en) 2004-08-04 2006-07-27 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US8864730B2 (en) 2005-04-12 2014-10-21 Rochester Medical Corporation Silicone rubber male external catheter with absorbent and adhesive
US8015990B2 (en) * 2006-11-17 2011-09-13 B. Braun Medical Inc. Needleless access port valves
US9695953B2 (en) * 2006-02-14 2017-07-04 B. Braun Medical Inc. Needleless access port valves
NZ572193A (en) 2006-03-31 2011-10-28 Quadra Logic Tech Inc Nasolacrimal drainage system implants for drug therapy with non-fluid swellable retention structure around drug core
DK2865361T3 (da) 2007-09-07 2019-07-08 Mati Therapeutics Inc Tåreimplantater og tilhørende fremgangsmåder
BRPI0817074A2 (pt) 2007-09-07 2015-03-24 Qlt Plug Delivery Inc Aparelho, método para tratar uma desordem ocular, dispositivo de detecção e sistema de detecção
NZ598483A (en) * 2007-09-07 2013-08-30 Quadra Logic Tech Inc Drug cores for sustained release of therapeutic agents
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
CN102105137B (zh) 2008-04-30 2015-01-07 Qlt股份有限公司 复合泪管植入物及相关方法
BRPI0912182A2 (pt) 2008-05-09 2015-10-06 Qlt Plug Delivery Inc distribuição de liberação prolongada de agentes ativos pára tratar glaucoma e hipertensão ocular
RU2011138947A (ru) 2009-02-23 2013-03-27 Клт Инк. Лакримальные имплантаты и связанные с ними способы
US9707375B2 (en) 2011-03-14 2017-07-18 Rochester Medical Corporation, a subsidiary of C. R. Bard, Inc. Catheter grip and method
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
CN103889401B (zh) 2011-08-29 2017-10-13 Qlt公司 持续释放递送活性剂以治疗青光眼和高眼压
US10092728B2 (en) 2012-11-20 2018-10-09 Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. Sheath for securing urinary catheter
US9872969B2 (en) 2012-11-20 2018-01-23 Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. Catheter in bag without additional packaging
WO2014179568A2 (en) * 2013-05-02 2014-11-06 Odin Biotech Two-layer ocular implant
CL2014000989A1 (es) * 2014-04-17 2014-10-17 Univ Santiago Chile Dispositivo subdermal de liberacion prolongada y lenta para prevencion, tratamiento y monitoreo de parasitos, que comprende al menos una lactona macrociclica tal como ivermectina y/o dormectina, opcionalmente nanoparticulas o microparticulas de zeolita, una matriz polimerica y medios de monitoreo, dentro de un circuito integrado.
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
CA2957085C (en) 2014-08-26 2023-01-17 C.R. Bard, Inc. Packaging and hydrophilic coating of urinary catheter
CN111107812A (zh) 2017-09-19 2020-05-05 C·R·巴德股份有限公司 导尿管桥接设备、***及其方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279996A (en) * 1962-08-28 1966-10-18 Jr David M Long Polysiloxane carrier for controlled release of drugs and other agents
US4053580A (en) * 1975-01-01 1977-10-11 G. D. Searle & Co. Microsealed pharmaceutical delivery device
IE56979B1 (en) * 1984-02-14 1992-02-26 Drug Systems Res & Dev Subcutaneous implant
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
US4861596A (en) * 1988-03-21 1989-08-29 Pfizer Inc. Rolled matrix device having enhanced ability to unroll and method for its production
FR2653338B1 (fr) * 1989-10-23 1994-06-10 Dow Corning Sa Formulation pour des pansements a liberation prolongee de medicament et son utilisation.
JPH05238929A (ja) * 1992-02-27 1993-09-17 Sumitomo Pharmaceut Co Ltd 代謝性骨疾患治療用長期持続性製剤
NZ302661A (en) * 1995-02-24 1999-10-28 Novartis Ag Composition for controlling parasites comprising n phenyl-n'-benzoylurea derivatives
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
AUPR602401A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system

Also Published As

Publication number Publication date
WO2003022242A1 (en) 2003-03-20
US20040234572A1 (en) 2004-11-25
JP2005505557A (ja) 2005-02-24
CN1541090A (zh) 2004-10-27
BR0212052A (pt) 2004-08-17
NZ530550A (en) 2004-11-26
CA2452194A1 (en) 2003-03-20
EP1424994A1 (en) 2004-06-09
EP1424994A4 (en) 2004-12-01

Similar Documents

Publication Publication Date Title
CO5560533A2 (es) Preparacion de una composicion farmaceutica de liberacion sostenida
AR046811A1 (es) Formas de dosificacion oral de ziprasidona de liberacion sostenida
ES2178268T3 (es) Formulaciones de liberacion controlada.
AR050533A1 (es) Composicion para el cuidado oral con peroxido polimerico con enlaces cruzados
CO5540373A2 (es) Composicion farmaceutica de liberacion sostenida
DE60005819D1 (de) Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
ES2192265T3 (es) Forma de dosificacion farmaceutica que enmascara el sabor y que se libera rapidamente.
DK2332523T3 (da) Ensartede film til hurtigtopløsende doseringsform indeholdende smagsmaskerende præparater
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
DOP2001000229A (es) Forma de dosificación de fármaco activada por hidrogel
CL2008000823A1 (es) Formulacion farmaceutica de liberacion inmediata que comprende dapagliflozina propilenglicol hidrato y un portador farmaceuticamente aceptable; uso para tratar diabetes, intolerancia a la glucosa, resistencia a la insulina, entre otras.
AR047586A1 (es) Una composicion de recubrimiento para la formacion de una capa inorganica sobre la superficie de un substrato
AR073704A1 (es) Sistema de administracion transdermal de droga para principios activos liquidos que tiene una capa de matriz adhesiva que incluye un ingrediente farmaceutico activo que es seleccionado entre selegilina y rivastigmina
UY24288A1 (es) Procedimiento para la preparación de una composición de liberación retardada de paroxetina
CY1108426T1 (el) Στοματικες μορφες χορηγησης για προπιβερινη ή φαρμακευτικως αποδεκτα αλατα αυτης με παρατεταμενη απελευθερωση της δραστικης ουσιας
AR058297A1 (es) Compuestos que contienen calciorecubiertos con una pelicula polimerica hidrosoluble y el uso de dichos compuestos recubiertos en composiciones farmaceuticas
BR0015605A (pt) Composição e uso
ES2166769T3 (es) Comprimido farmaceutico de liberacion controlada que presenta forma lenticular.
DE602006016127D1 (de) Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
AR037407A1 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus de tipo ii
CO5690532A2 (es) Formas de dosificacion farmaceutica de liberacion extendida
AR033946A1 (es) Un sistema terapeutico transdermal que comprende microreservorios y un procedimiento para la manufactura de sistemas de microreservorios basados en polisiloxanos y solventes ambifilos.
CO5601036A2 (es) Composicion farmaceutica de liberacion sostenida
ATE303137T1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit
AR032642A1 (es) Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponibilidad oral.

Legal Events

Date Code Title Description
FA Application withdrawn